Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY | Market Cap | 7.02T |
| Revenue (ttm) | 4.42T |
| Net Income (ttm) | 33.08B |
| Shares Out | 1.58B |
| EPS (ttm) | 20.62 |
| PE Ratio | 215.48 |
| Forward PE | 27.56 |
| Dividend | 200.00 (4.57%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 6,063,400 |
| Average Volume | 4,759,590 |
| Open | 4,388.00 |
| Previous Close | 4,380.00 |
| Day's Range | 4,354.00 - 4,443.00 |
| 52-Week Range | 3,916.00 - 4,670.00 |
| Beta | 0.03 |
| RSI | 63.85 |
| Earnings Date | Oct 30, 2025 |
About TYO:4502
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]
Full Company ProfileFinancial Performance
In 2024, TYO:4502's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.
Financial StatementsNews
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile
On Monday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it ...
Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) announced new interim findings from its Phase 1b open-label proof-of-concept trial evaluating subcutaneous mezagitamab (TAK-079), an anti-CD38 m...
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079...
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial...
Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Takeda Pharmaceutical Company Limited ( TAK) Q2 2026 Earnings Call October 30, 2025 6:00 AM EDT Company Participants Christopher David O'Reilly - Global Head of Investor Relations & Global Finance Ch...
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion).
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges
Takeda Pharmaceutical Company Limited (NYSE: TAK) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen (approximately $1.31 billion). The company reported earnings per Ameri...
Takeda Pharmaceutical Company Limited 2026 Q2 - Results - Earnings Call Presentation
Takeda Pharma H1 Net Profit Declines; Revenue Down 6.9%
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) reported first half net profit to owners of company of 112.4 billion yen, down 40.0% from prior year. Earnings per share was 70.45 yen compared ...
Takeda Pharmaceutical Q2 25 Earnings Conference Call At 6:00 AM ET
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK) will host a conference call at 6:00 AM ET on October 30, 2025, to discuss Q2 25 earnings results.
Takeda Pharmaceutical (TAK) Adjusts Financial Guidance for FY2025
Takeda Pharmaceutical (TAK) Adjusts Financial Guidance for FY2025
Takeda Pharmaceutical Non-GAAP EPS of ¥279.00, revenue of ¥2219.5B; updates FY outlook
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment.
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. T...
Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings Report Preview: What To Look For
Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings Report Preview: What To Look For
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
China's Innovent Biologics said on Wednesday it had signed an $11.4 billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate ...
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innoven...
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for th...
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact
Nabla Bio , a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE...
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership
U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical , deepening their use of artificial intelligence to accelera...
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nabla Bio, a biotechnology company pioneering de novo therapeutics design with generative AI, today announced a new, multi-year research collaboration with Takeda. U...
Takeda Pharmaceutical Becomes Oversold (TAK)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...